ZIELINSKI, R. R.; AZAD, A. A.; CHI, K. N.; TYLDESLEY, S. Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer. Canadian Urological Association Journal, [S. l.], v. 8, n. 7-8, p. e520–3, 2014. DOI: 10.5489/cuaj.2076. Disponível em: https://cuaj.ca/index.php/journal/article/view/2076. Acesso em: 19 apr. 2024.